Solara Active appoints PV Raghavendra Rao as chief financial officer

Rao is a chartered accountant from the Institute of Chartered Accountants of India (ICAI) and has about two and half decades of post-qualification experience

Solara Active Pharma
Solara Active Pharma
BS Web Team New Delhi
2 min read Last Updated : Oct 19 2023 | 6:24 PM IST

Don't want to miss the best from Business Standard?

Drugmaker Solara Active Pharma Sciences on Thursday announced that PV Raghavendra Rao has been appointed as the chief financial officer (CFO) of the company and has been given the designation of key managerial personnel. The appointment is effective from October 26, the company said in a press release. 

Rao is a chartered accountant from the Institute of Chartered Accountants of India (ICAI) and has about two and half decades of post-qualification experience. Rao has a strong track record of handling multiple industries, including pharmaceuticals, the company said.

Rao will join Solara Sequent Scientific Limited, where he was the chief financial officer. Previously, he was at Macleods Pharmaceuticals Ltd and Dr Reddy's Laboratories Limited, for over 14 years where he handled various roles in finance. Rao also has experience in handling manufacturing plants spread across India and overseas, along with experience in strategy, identifying moves and handling strategy deployment processes.

Raghavendra Rao had resigned from the role of chief financial officer of Sequent Scientific Limited with effect from October 25

According to the company's exchange filing, "We wish to inform you that PV Raghavendra Rao, chief financial officer and key managerial personnel of the company has resigned today i.e., October 16, 2023, due to personal reasons, which require him to relocate out of Mumbai. He will continue in his current role till the close of business hours on October 25, 2023."

On September 7, Solara Active Pharma's promoters Karuna Business Solutions offloaded a 2.04 per cent stake in the company. Spiracca Ventures was the buyer in the block deal, picking up the stake at a value of Rs 270.54 crore.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Solara Active Pharma SciencesPharma sectorPharma CompaniesBS Web Reports

First Published: Oct 19 2023 | 6:24 PM IST

Next Story